治疗公司（Therapeutics Inc.）是一家早期阶段的RNAi药物开发商，在美国首次公开发行中以发行区间中点价格筹集了2亿美元。
Therapeutics Inc., an early-stage developer of RNAi-based drugs, raised $200 million in a US initial public offering priced at the mid-point of its marketed range.
根据10月15日的声明，该公司投资者包括Arch Venture Partners和Fidelity Management & Research，以每股18美元的价格售出1110万股。其向美国证券交易委员会提交的文件显示，该公司此前在17至19美元区间推广了972万股。
The company, which counts Arch Venture Partners and Fidelity Management & Research among its investors, sold 11.1 million shares for $18 apiece, according to a statement dated Oct. 15. City had marketed 9.72 million shares for $17 to $19 each, its filings with the US Securities and Exchange Commission show.
按IPO价格计算，总部位于马萨诸塞州剑桥的公司，根据其文件中的流通股股份，市值约为9.06亿美元。
At the IPO price, the Cambridge, Massachusetts-based firm would have a market value of roughly $906 million, based on the outstanding shares in its filings.
该公司正在开发RNAi药物以治疗血栓栓塞性疾病和Stargardt病——一种发生在儿童和年轻成人中的遗传性黄斑变性疾病。公司的领先产品正处于早期阶段的临床试验中，其他产品候选者正处于临床前开发或药物发现阶段。公司预计将在今年公布I期研究的数据。
City is developing RNAi-based drugs to treat thromboembolic diseases and Stargardt disease, an inherited macular degenerative disease in children and young adults. The firm’s lead product is in an early-stage trial, and other product candidates are in preclinical development or drug discovery. City expects to report data from the phase 1 study this year.
此次发行紧随基因疗法同行开发商Adarx Pharmaceuticals Inc.受到投资者热烈欢迎之后——该公司上月在首次公开发行中筹集了约4.46亿美元。根据彭博社编译的数据，今年生物技术和制药领域的新进入者已筹集80亿美元，而2025年同期为13亿美元。
The offering follows investors’ warm welcome to peer gene therapy developer Adarx Pharmaceuticals Inc., which raised about $446 million in its debut last month. New entrants in biotech and pharma have raised $8 billion this year, versus $1.3 billion in the corresponding period in 2025, according to data compiled by Bloomberg.
该公司分别与博士伦公司（Bausch + Lomb Corp.）和Biogen公司（Biogen Inc.）建立了战略合作，以推进用于眼部和中枢神经系统疾病的RNAi疗法。
City has strategic collaborations with Bausch + Lomb Corp. and Biogen Inc. to advance RNAi therapeutics for diseases of the eye and the central nervous system, respectively.
RNAi药物开发商Alnylam Pharmaceuticals Inc.的创始首席执行官John Maraganore共同创立了该公司，并担任其执行董事长。
John Maraganore, the founding chief executive officer of RNAi drug developer Alnylam Pharamaceuticals Inc., co-founded City and serves as its executive chair.
该公司在截至2026年6月30日的六个月内，合作收入为640万美元，净亏损为5340万美元；而去年同期收入为560万美元，净亏损为2430万美元，其提交的文件显示。
City had a net loss of $53.4 million on collaboration revenue of $6.4 million in the six months ended June 30, 2026, compared with a net loss of $24.3 million on revenue of $5.6 million a year earlier, the filing shows.
根据其文件显示，该公司自2023年成立以来至6月30日已通过私募融资筹集了2.388亿美元。文件显示，发行后Arch预计将控制公司约27%的股份，而富达将持有7.6%的股份。
City has raised $238.8 million in private funding since it was founded in 2023 through June 30, according to its filings. Arch is expected to control about 27% of the company after the offering, while Fidelity will have a 7.6% stake, the filing shows.
此次发行由高盛集团公司、杰富瑞金融集团公司、斯蒂费尔金融公司和奥本海默公司牵头。股票预计将于周五在纳斯达克全球市场以代码CTY开始交易。
The offering was led by Goldman Sachs Group Inc., Jefferies Financial Group Inc., Stifel Financial Corp. and Oppenheimer & Co. Shares are expected to begin trading Friday on the Nasdaq Global Market under the symbol CTY.